ArticleBMC medicine2026
Clonal haematopoiesis of indeterminate potential and risk of incident psychiatric disorders.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExploring the association of clonal haematopoiesis of indeterminate potential (CHIP) with psychiatric disorders (PDs) may help to elucidate the biological mechanisms underlying PDs. The study aimed to identify the specific PD subtypes associated with CHIP and gene-specific CHIP for each PD subtype.
methodsA total of 360,451 participants from UK Biobank without PDs at baseline, aged 40-69 years and recruited between 2005 and 2014, were included. CHIP status was determined from whole exome sequencing for mutations in 74 driver genes. Any CHIP (variant allele fraction (VAF) ≥ 2%), large CHIP (VAF ≥ 10%), and gene-specific CHIP were set as exposures. The primary outcomes were overall psychiatric disorder with 13 PD subtypes. Brain imaging-derived phenotypes (IDPs), derived from 40,000 individuals during follow-up, were further included.
resultsDuring a median follow-up of 13.6 years, 50,074 (13.9%) participants developed at least one PD. This prospective study demonstrated that CHIP and large CHIP were independently associated with a 15% (10%-20%) and 27% (18%-36%) increased risk of PDs. Among PD subtypes, CHIP and large CHIP were associated with hazard ratios (HR) of 1.12 (1.04-1.21) and 1.27 (1.11-1.44) for major depressive disorders, and 1.27 (1.20-1.35) and 1.21 (1.09-1.34) for substance use disorders, respectively. Gene-specific analyses revealed that risk for PDs was generally increased across CHIP driven by seven genes (DNMT3A, TET2, ASXL1, PPM1D, SRSF2, NF1, SF3B1) with the highest mutation frequency. Associations of gene-specific CHIP were also heterogeneous across PD subtypes. Furthermore, CHIP carries, especially DNMT3A-CHIP carries, had significant changes in 11 brain white matter (WM) tract IDPs.
conclusionsCHIP was associated with elevated risk of psychiatric disorders, specifically major depressive disorders and substance use disorders, with gene-specific associations observed with changes in brain WM tracts. These findings revealed a potential biological association between CHIP and psychiatric disorders, offering new insights into disease mechanisms and possible therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.